Twenty years of switching neurons with light have mapped memory, movement, sleep and reward. Here is what optogenetics has shown, and why it is not yet a treatment.
For most of its history, neuroscience was an observational science. Researchers could watch which parts of the brain grew active when an animal remembered, moved or slept, and they could study what went wrong after injury. What they could not do was reach in, switch on one kind of neuron and see whether the behaviour followed. Optogenetics, the method behind this year’s Nobel Prize in Physiology or Medicine, made that possible. Thomas Perlmann, secretary-general of the Nobel Assembly, put it simply: the method makes it possible to switch the activity of individual nerve cells on or off in a living brain.
Two decades of experiments, mostly in mice, show what that power has meant.
Memories that can be switched on
One of the most striking results came in 2012 from a team at the Massachusetts Institute of Technology. The researchers labelled the neurons in the hippocampus that were active while a mouse learned to fear a particular box. Days later, with the mouse in a completely different and harmless place, they shone light on those same neurons. The mouse froze, as if it were back in the frightening box. A memory, it turned out, lives at least partly in a specific set of cells, and activating those cells is enough to recall it.
Later work by the same group went further, linking such stored memories to new experiences in ways that changed how the animals behaved. For a field that had argued for a century over where and how memories are stored, these were direct tests rather than inferences.
Movement, reward and sleep
Optogenetics also sharpened old theories about movement. A long-standing model held that two pathways in a deep brain structure, the striatum, act like an accelerator and a brake. In 2010 researchers switched on each pathway separately in mice. Activating one made the animals move more; activating the other made them freeze and move less, much as in Parkinson’s disease. A diagram drawn from decades of indirect evidence was confirmed in a single, clean experiment.
The same logic has been applied to reward. Brief bursts of light on dopamine neurons were enough to make mice prefer the place where the light had come on, showing how those neurons teach an animal what is worth seeking. In sleep research, switching on a small group of hypothalamic neurons made sleeping mice more likely to wake, linking those cells directly to arousal. Similar experiments have probed anxiety, aggression, hunger, thirst and social behaviour.
The common thread is causation. Before optogenetics, these were correlations: a region was active during a behaviour. Afterwards, they were mechanisms: activating this cell type produces that behaviour, and silencing it prevents it.
The clinical frontier
It is natural to ask when optogenetics will treat patients. The most advanced attempt so far is in the eye. In 2021 researchers reported that a man blinded by retinitis pigmentosa, an inherited disease that destroys the retina’s light-sensing cells, had partly recovered vision after gene therapy gave other retinal cells a light-sensitive protein. Wearing special goggles that converted the scene into bright pulses of light, he could locate and count objects on a table. It was one patient, and the vision was crude, but it was a real proof that the approach can work in people.
The eye is a special case. Light reaches the retina naturally, and the eye is small, accessible and partly shielded from the immune system. The brain offers none of these advantages. Getting light deep into human tissue is one of the main obstacles to clinical use. A treatment would need a safe way to deliver genes into the right human neurons, protein expression that lasts for years without provoking an immune reaction, and an implanted light source that does not damage tissue.
That is why the honest description, used by India’s own science portal in its coverage of the prize, is that optogenetics is a research technique, not an established treatment for neurological disorders. Its medical value today is mostly indirect. By showing which circuits go wrong in conditions such as Parkinson’s disease, depression or addiction, it helps refine treatments that already exist, including drugs and deep brain stimulation, and points to new targets.
The limits scientists worry about
Researchers who use optogenetics every day are also its sharpest critics. Light-driven activation makes many neurons fire together in a neat rhythm, which is not how real brain activity looks, so an animal’s response may partly reflect an unnatural signal. Strong light can warm tissue, and heat alone can change how neurons behave. And mice are not people: a circuit that controls fear in a mouse may be organised quite differently in the human brain.
None of this diminishes the achievement. It defines it. Optogenetics did not explain the brain. It gave neuroscience a way to ask precise questions and get clear answers, one circuit at a time.
For the three laureates, the prize honours a protein from a pond alga and the insight that turned it into a switch. For neuroscience, it marks the moment the field stopped merely watching the brain and started testing it.
– Dr Srinayana Kavuri
